Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoSarc: Pembrolizumab +/- Olaparib in Resectable STS
NCT06116578Phase 2Withdrawn
- Sponsor
- Gustave Roussy
- Start
- Jan 2025
- Primary completion
- Jul 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, olaparib in soft tissue sarcoma (STS), sponsored by Gustave Roussy. Planned start Jan 2025; status: withdrawn.
02
Drugs
pembrolizumabolaparib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT06116578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06116578.